Autologous BMT in high risk patients with CALLA-positive ALL: Possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement

Y. Morishima, K. Miyamura, S. Kosjima, R. Ueda, Y. Morishita, H. Sao, M. Tanimoto, R. Ohno, R. Sobue, M. Hirano, H. Sakamaki, S. Takamoto, K. Imai, Y. Onozawa, S. Yokomaku, Y. Kato, S. Tsuzuki, Yoshiki Akatsuka, S. Minami

研究成果: Article

17 引用 (Scopus)

抄録

Autologous BMT (auto-BMT) has been conducted for 17 high-risk common ALL antigen (CALLA)-positive non-T cell type ALL patients. Ex vivo purging of leukemia cells from infused BM cells was performed using complement and three kinds of mouse monoclonal antibodies reactive to CALLA-positive leukemia cells: NL-1 (IgG2a), NL-22 (IgM), and HL-47 (IgM). Minimal residual leukemia cells in BM were examined by PCR method in Philadelphia chromosome (Ph1)-positive ALL cases. BCR/ABL chimeric transcript, which was positive in BM samples before purging, was shown to be absent after ex vivo purging in all three cases tested. Among four Ph1-positive cases transplanted in first CR, three cases survived in CR remission 77, 29 and 26 months after BMT, and one case died without relapse 4 months after BMT. The other four Ph1-negative cases transplanted in the first CR also remained in CR except one who relapsed. The results of minimal residual leukemia cell studies and clinical data indicate the effectiveness of our ex vivo leukemia cell purging method and auto-BMT in the early stage of CR for patients with high risk ALL.

元の言語English
ページ(範囲)255-259
ページ数5
ジャーナルBone Marrow Transplantation
11
発行部数4
出版物ステータスPublished - 01-01-1993

Fingerprint

Leukemia
Bone Marrow
Monoclonal Antibodies
Antigens
Immunoglobulin M
Philadelphia Chromosome
Recurrence
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

これを引用

Morishima, Y. ; Miyamura, K. ; Kosjima, S. ; Ueda, R. ; Morishita, Y. ; Sao, H. ; Tanimoto, M. ; Ohno, R. ; Sobue, R. ; Hirano, M. ; Sakamaki, H. ; Takamoto, S. ; Imai, K. ; Onozawa, Y. ; Yokomaku, S. ; Kato, Y. ; Tsuzuki, S. ; Akatsuka, Yoshiki ; Minami, S. / Autologous BMT in high risk patients with CALLA-positive ALL : Possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. :: Bone Marrow Transplantation. 1993 ; 巻 11, 番号 4. pp. 255-259.
@article{207e0c8a38d245c8b29bf58524f125ea,
title = "Autologous BMT in high risk patients with CALLA-positive ALL: Possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement",
abstract = "Autologous BMT (auto-BMT) has been conducted for 17 high-risk common ALL antigen (CALLA)-positive non-T cell type ALL patients. Ex vivo purging of leukemia cells from infused BM cells was performed using complement and three kinds of mouse monoclonal antibodies reactive to CALLA-positive leukemia cells: NL-1 (IgG2a), NL-22 (IgM), and HL-47 (IgM). Minimal residual leukemia cells in BM were examined by PCR method in Philadelphia chromosome (Ph1)-positive ALL cases. BCR/ABL chimeric transcript, which was positive in BM samples before purging, was shown to be absent after ex vivo purging in all three cases tested. Among four Ph1-positive cases transplanted in first CR, three cases survived in CR remission 77, 29 and 26 months after BMT, and one case died without relapse 4 months after BMT. The other four Ph1-negative cases transplanted in the first CR also remained in CR except one who relapsed. The results of minimal residual leukemia cell studies and clinical data indicate the effectiveness of our ex vivo leukemia cell purging method and auto-BMT in the early stage of CR for patients with high risk ALL.",
author = "Y. Morishima and K. Miyamura and S. Kosjima and R. Ueda and Y. Morishita and H. Sao and M. Tanimoto and R. Ohno and R. Sobue and M. Hirano and H. Sakamaki and S. Takamoto and K. Imai and Y. Onozawa and S. Yokomaku and Y. Kato and S. Tsuzuki and Yoshiki Akatsuka and S. Minami",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "11",
pages = "255--259",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

Morishima, Y, Miyamura, K, Kosjima, S, Ueda, R, Morishita, Y, Sao, H, Tanimoto, M, Ohno, R, Sobue, R, Hirano, M, Sakamaki, H, Takamoto, S, Imai, K, Onozawa, Y, Yokomaku, S, Kato, Y, Tsuzuki, S, Akatsuka, Y & Minami, S 1993, 'Autologous BMT in high risk patients with CALLA-positive ALL: Possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement', Bone Marrow Transplantation, 巻. 11, 番号 4, pp. 255-259.

Autologous BMT in high risk patients with CALLA-positive ALL : Possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. / Morishima, Y.; Miyamura, K.; Kosjima, S.; Ueda, R.; Morishita, Y.; Sao, H.; Tanimoto, M.; Ohno, R.; Sobue, R.; Hirano, M.; Sakamaki, H.; Takamoto, S.; Imai, K.; Onozawa, Y.; Yokomaku, S.; Kato, Y.; Tsuzuki, S.; Akatsuka, Yoshiki; Minami, S.

:: Bone Marrow Transplantation, 巻 11, 番号 4, 01.01.1993, p. 255-259.

研究成果: Article

TY - JOUR

T1 - Autologous BMT in high risk patients with CALLA-positive ALL

T2 - Possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement

AU - Morishima, Y.

AU - Miyamura, K.

AU - Kosjima, S.

AU - Ueda, R.

AU - Morishita, Y.

AU - Sao, H.

AU - Tanimoto, M.

AU - Ohno, R.

AU - Sobue, R.

AU - Hirano, M.

AU - Sakamaki, H.

AU - Takamoto, S.

AU - Imai, K.

AU - Onozawa, Y.

AU - Yokomaku, S.

AU - Kato, Y.

AU - Tsuzuki, S.

AU - Akatsuka, Yoshiki

AU - Minami, S.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Autologous BMT (auto-BMT) has been conducted for 17 high-risk common ALL antigen (CALLA)-positive non-T cell type ALL patients. Ex vivo purging of leukemia cells from infused BM cells was performed using complement and three kinds of mouse monoclonal antibodies reactive to CALLA-positive leukemia cells: NL-1 (IgG2a), NL-22 (IgM), and HL-47 (IgM). Minimal residual leukemia cells in BM were examined by PCR method in Philadelphia chromosome (Ph1)-positive ALL cases. BCR/ABL chimeric transcript, which was positive in BM samples before purging, was shown to be absent after ex vivo purging in all three cases tested. Among four Ph1-positive cases transplanted in first CR, three cases survived in CR remission 77, 29 and 26 months after BMT, and one case died without relapse 4 months after BMT. The other four Ph1-negative cases transplanted in the first CR also remained in CR except one who relapsed. The results of minimal residual leukemia cell studies and clinical data indicate the effectiveness of our ex vivo leukemia cell purging method and auto-BMT in the early stage of CR for patients with high risk ALL.

AB - Autologous BMT (auto-BMT) has been conducted for 17 high-risk common ALL antigen (CALLA)-positive non-T cell type ALL patients. Ex vivo purging of leukemia cells from infused BM cells was performed using complement and three kinds of mouse monoclonal antibodies reactive to CALLA-positive leukemia cells: NL-1 (IgG2a), NL-22 (IgM), and HL-47 (IgM). Minimal residual leukemia cells in BM were examined by PCR method in Philadelphia chromosome (Ph1)-positive ALL cases. BCR/ABL chimeric transcript, which was positive in BM samples before purging, was shown to be absent after ex vivo purging in all three cases tested. Among four Ph1-positive cases transplanted in first CR, three cases survived in CR remission 77, 29 and 26 months after BMT, and one case died without relapse 4 months after BMT. The other four Ph1-negative cases transplanted in the first CR also remained in CR except one who relapsed. The results of minimal residual leukemia cell studies and clinical data indicate the effectiveness of our ex vivo leukemia cell purging method and auto-BMT in the early stage of CR for patients with high risk ALL.

UR - http://www.scopus.com/inward/record.url?scp=0027463158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027463158&partnerID=8YFLogxK

M3 - Article

C2 - 7683550

AN - SCOPUS:0027463158

VL - 11

SP - 255

EP - 259

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -